Industries > Pharma > Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024

Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024

PUBLISHED: 02 December 2013
PAGES: 139
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
SKU: N/A Categories: ,

Analysis of revenues and R&D prospects for those eye drugs – you explore potentials

What's the future for treating disorders of the retina? Visiongain's updated report forecasts those pharma revenues. There you find outlooks for sales growth in that industry. You also explore trends, technologies, therapies, and opportunities.

That analysis gives you predictions of revenues to 2024 at overall world market, submarket, product, and national level. Avoid falling behind in data, then, missing business or losing influence. So find what's happening for those ocular medicines. Discover how you can gain.

Read on to explore those products and see what their future could be worth.

Forecasts and other information to benefit your research and analyses

Besides revenue forecasting to 2024, our new work shows historical data, growth rates, and market shares. There you find original analysis. Explore research and development (R&D) too. You also get 36 tables, 38 charts, and two interviews with other authorities.

Anyhow, the future appears promising for companies treating those eye disorders.

Ophthalmic technology – find growth opportunities and how to help your work

That new study lets you investigate the most promising and lucrative treatments for neovascularisation and other rear eye ailments. You explore technologies and applications.

There you hear what's happening and discover where the money lies. So benefit your research, analyses, and decisions. Stay ahead, then, without missing out. See, too, how you could extend your influence.

The following sections explain what you get in our new investigation.

Forecasting the world market and segments for medicines treating retinal disorders

What're the secrets of that technology's progress? What's its potential? Find in our report overall world revenue to 2024 for retinal medicines.

Also explore individual revenue predictions to 2024 for four therapeutic submarkets at world level:
• Wet age-related macular degeneration (AMD)
• Dry AMD
• Diabetic retinopathy (DR)
• Other retinal diseases.

Where lie the best prospects? There you assess outlooks for revenue expansion, seeing where you can gain.

That work also covers geographic atrophy (GA) and diabetic macular oedema/edema (DME), as well as proliferative and non-proliferative diabetic retinopathy.

You find sales predictions by product, too, hearing how they can succeed.

Predictions of leading products' sales

How will individual drugs perform from 2013 to 2024 at world level? Our study forecasts revenues of three established brands:
• Lucentis
• Eylea
• Avastin.

There you discover how high sales can go, finding agents and years with highest predicted revenues. Also examine competition. You see what's happening, then, understanding challenges, trends, competitors, and opportunities.

Single and combination treatments matter. Our report explains. That work also shows you geographical predictions.

Healthcare in national markets – what outlooks for retinal medical sales?

Advances in biotechnology and pharmaceuticals expand use of drugs to treat back-of-eye impairments and vision loss. You gain feel for those technologies' revenue prospects.

Our work shows you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Japan
• EU leaders – Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations – Brazil, Russia, India, and China.

There you find countries with highest revenues and potential growth. You explore outlooks for treating ocular problems, serving needs. Assess opportunity. Discover, then, how you and your organisation can gain.

You also examine developments leading to novel treatments.

Developing products – discover trends, innovations, and progress

You also investigate R&D, appraising technological and commercial possibilities.

So assess research and developments to slow vision loss and restore sight. Our report discusses these advances and others:
• Combination therapies, inc. neovascularisation cascade blockers
• Blocking pericyte recruitment
• Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis)
• Monoclonal antibodies (mAbs), mAb fragments, DARPins (designed ankyrin repeat proteins), and visual cycle modulators
• Anti-inflammatory mechanisms (inc. corticosteroids).

And agents including these:
• Complement factor inhibition and serotonin modifiers
• Anti-integrin oligopeptide treatment
• Oligonucleotides and siRNA therapy
• Angiotensin receptor blockers and converting enzyme inhibitors
• Regenerative medicine, neural stem cells, cellular and gene therapies.

R&D there holds strength, variety, and promise. See what's possible for big pharma companies and specialists in biological drugs (biologics) and other biotechnologies.

You explore progress, then, assessing that industry's participants and their futures.

Companies and overall 2017 market value – what predicted revenues?

Our analyses predict the world market for retinal drugs will reach $9.8bn in 2017. It will rise with double-digit growth during our forecasted period. You find how high sales can go.

You also see what organisations hold most potential. Examine companies including these:
• Novartis
• Roche
• Regeneron
• Bayer
• Neurotech Pharmaceuticals
• Allergan.

You find 135 organisations mentioned. Also read two interviews with authorities on retinal conditions. Discover, then, what that field does, says, and thinks. Now you can stay ahead.

Ways Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024 helps you

In particular, our new investigation gives you this knowledge:
• Revenues to 2024 for retinal medications at overall world level, 4 submarkets, and 3 top products – assess prospects for investments, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia -investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants – examine portfolios, results, R&D, and outlooks for success.

Information found nowhere else, letting you appraise medicines in ophthalmics

That new report gives independent analysis. There you receive competitive intelligence found only in our work, finding where the money lies. Explore progress and possibilities.

With that data you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find how you could save time and effort there, also benefiting your authority.

Ordering now lets you discover commercial predictions, getting information you need

Our new report shows you data, trends, opportunities, and sales predictions to 2024 for retinal pharma. Try that study. So avoid missing out – please order now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024

Download sample pages

Complete the form below to download your free sample pages for Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024

Latest Pharma news

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022


Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022


Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022


Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022